Radionuclide

Nusano Expands Executive Management to Support Q1 2025 Radioisotope Commercialization

Retrieved on: 
水曜日, 5月 29, 2024
Novartis, API, Health, Risk, Bedekar, CFO, Drug development, Cancer, Physics, Treasury, Medicine, Regulatory affairs, Radionuclide, Quality assurance, Actinium-225, Pharmaceutical industry

These appointments provide additional leadership and experience as the company begins commercial-scale radioisotope shipments to customers in Q1 2025.

Key Points: 
  • These appointments provide additional leadership and experience as the company begins commercial-scale radioisotope shipments to customers in Q1 2025.
  • “Nusano continues to attract best-in-class talent as we revolutionize radioisotope production to supply the fight against cancer,” said Chris Lowe, CEO of Nusano.
  • Their combined expertise and talents will be instrumental as we continue to expand our capabilities and prepare for commercialization beginning in Q1 2025."
  • The company expects to begin producing and delivering commercial-scale quantities of lutetitum-177 in Q1 2025 and actinium-225 in H2 2025.

Interim Management Statement Q1 2024 of Molecular Partners: Pipeline Progressing with Two Additional Programs to Enter the Clinic in 2025, Update to MP0533 Program

Retrieved on: 
木曜日, 5月 16, 2024
Partnership, Molecular imaging, Delta, Novartis, HSC, IND, Bone marrow, Cytokine release syndrome, Congress, AML, CD70, EHA, Hematopoietic stem cell transplantation, Depreciation, Therapy, District court, Molecule, CD33, Conference, CD47, Society, Annual, Alpha particle, B cell, Physician, Half-life, DARPin, ASH, DRS, Stem cell, Molecular Partners, Safety, Tetra, Gene family, ASCO, FAP, Radionuclide, DLL3, CD40, CHF, European Hematology Association, Antigen, Patient, Prejudice, HSCT, SNMMI, Partner, RDT, ELN, CD123, DSM-IV codes, Pharmaceutical industry

For our emerging pipeline, we plan to announce preclinical data from our Switch-DARPin Platform at EHA and anticipate translational efficacy data in the second half of 2024.

Key Points: 
  • For our emerging pipeline, we plan to announce preclinical data from our Switch-DARPin Platform at EHA and anticipate translational efficacy data in the second half of 2024.
  • Of this figure, approximately CHF 8 million will be non-cash effective costs for share-based payments, IFRS pension accounting and depreciation.
  • With CHF 174.1 million in cash and short-term time deposits and no debt as of March 31, 2024, the Company expects to be funded well into 2026.
  • The first Switch-DARPin program (cKIT x CD16a x CD47) was introduced at the annual J.P. Morgan Healthcare Conference in January 2024.

ispace and University of Leicester Collaborate on Lunar Night Survival Technology

Retrieved on: 
木曜日, 5月 23, 2024
Technology, Satellite, Aerospace, Manufacturing, Energy, Nuclear, Hardware, University, Education, Mission, Transport, Australian Space Agency, Ministry, Moon, ESA, Spacecraft, Physics, National Nuclear Laboratory, Exploration, Lunar lander, Astronomy, UK Space Agency, Sunlight, European Space Agency, Rover, Attention, I-Space, Radionuclide, Electricity, Multimedia, Water heating

ispace, inc. (ispace), a global lunar exploration company, and the University of Leicester, have agreed to collaborate on approaches to lunar night survivability for future ispace lunar lander and rover missions.

Key Points: 
  • ispace, inc. (ispace), a global lunar exploration company, and the University of Leicester, have agreed to collaborate on approaches to lunar night survivability for future ispace lunar lander and rover missions.
  • View the full release here: https://www.businesswire.com/news/home/20240522837535/en/
    The University and ispace have entered into a strategic consulting agreement to explore lunar night survivability utilizing Radioisotope Heater Units on the Series 3 lunar lander and rovers.
  • To realize long-term missions, new technology and systems are required to survive the cryogenic environment of lunar night.
  • The Space Nuclear Power group at the University of Leicester has been developing radioisotope power systems for over a decade.

Oklo Signs MOU with Atomic Alchemy to Collaborate on Isotope Production

Retrieved on: 
月曜日, 5月 13, 2024
Software, Utilities, Hardware, Alternative Energy, Energy, Technology, Nuclear, Security, Partnership, Isotope, De Witte, Tritium, Science, Element, Inc., Cancer, Radionuclide, Artificial intelligence, Multimedia, Lithium

Oklo Inc. (NYSE: OKLO) (“Oklo” or the “Company”), a fast fission clean power technology and nuclear fuel recycling company, is forming a strategic partnership with Atomic Alchemy Inc. (“Atomic Alchemy”) to produce isotopes.

Key Points: 
  • Oklo Inc. (NYSE: OKLO) (“Oklo” or the “Company”), a fast fission clean power technology and nuclear fuel recycling company, is forming a strategic partnership with Atomic Alchemy Inc. (“Atomic Alchemy”) to produce isotopes.
  • This partnership will aim to combine Oklo’s work to build and operate fast reactors and fuel recycling expertise with Atomic Alchemy’s expertise in isotope production to meet increasing demands for isotopes.
  • I’m proud to be partnering with Oklo to help expand our domestic supplies of isotopes and tritium,” said Founder and CEO of Atomic Alchemy, Thomas Eiden.
  • Atomic Alchemy is advancing its mission through the construction of a scalable, fully vertically integrated radioisotope production facility.

ITM Appoints Dr. Danielle Meyrick as Chief Medical Officer

Retrieved on: 
火曜日, 5月 7, 2024
Murdoch University, University, Cancer, CMO, Hospital, Research, Nuclear medicine, MD, Strategic planning, Radionuclide, Patient, GenesisCare, Fremantle Hospital, ITM, Biotechnology, Medical imaging

Dr. Meyrick brings more than 20 years of medical research, radiotheranostic drug development and management experience to ITM.

Key Points: 
  • Dr. Meyrick brings more than 20 years of medical research, radiotheranostic drug development and management experience to ITM.
  • Before joining ITM, Dr. Meyrick was Chief Scientific Officer, Research and Insights at GenesisCare where she spearheaded medical and clinical strategies with a focus on radiopharmaceutical development.
  • Dr. Meyrick also served as the consulting Chief Medical Officer at AdvanCell Isotopes where she led clinical development efforts across pipeline assets.
  • As Chief Medical Officer, APAC and Global Head of Clinical Science at Telix Pharmaceuticals, Dr. Meyrick oversaw the clinical development of theranostic radiopharmaceutical candidates in the Asia Pacific region and supported commercial strategic planning efforts.

Monopar Announces Filing of Patent Protecting MNPR-101 Radiopharma Optimization Findings

Retrieved on: 
火曜日, 4月 16, 2024
Receptor (biochemistry), Cancer, MD, Radionuclide, Patent, Patient, Therapy, Pharmaceutical industry

Monopar expects this provisional patent application to further strengthen its intellectual property around the MNPR-101 radiopharma program, under which the Company is aiming to develop therapies for numerous hard-to-treat advanced cancers that express uPAR.

Key Points: 
  • Monopar expects this provisional patent application to further strengthen its intellectual property around the MNPR-101 radiopharma program, under which the Company is aiming to develop therapies for numerous hard-to-treat advanced cancers that express uPAR.
  • Monopar recently announced the initiation of its Phase 1 dosimetry clinical trial for MNPR-101-Zr in patients with advanced cancers.
  • “Filing of this provisional patent application is aimed at further protecting our novel MNPR-101 radiopharmaceutical program,” said Chandler Robinson, MD, Monopar’s Chief Executive Officer.
  • “This patent filing along with our earlier patent filings helps to create a broad portfolio of intellectual property around this program and potential future programs.”

ASP Isotopes Issues Letter to Stockholders

Retrieved on: 
木曜日, 4月 11, 2024
Consensus, FDA, Nuclear energy, Uranium, Memorandum, Void coefficient, SMR, Intelligence, Prostate cancer, Isotope, ASP, Silicon, Annual report, Yoy, PET, Semiconductor, Private, DOE, Acceleration, Safety, GE HealthCare, Small modular reactor, Artificial intelligence, Coal, Nuclear Energy Institute, Exercise, Isotopes of ytterbium, NEI, Cyclotron, Laser, Radiopharmaceutical, Government, FDG, Silane, Sale, Lithium, Lutetium (177Lu) vipivotide tetraxetan, LEU, Lutetium, Radionuclide, Electronics, ASPI, Letter, Growth, Rare-earth element

WASHINGTON, April 11, 2024 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. NASDAQ: ASPI ("ASPI,” or the “Company”), an advanced materials company dedicated to the development of technology and processes designed to produce isotopes used in multiple industries, today released the following letter to stockholders from its Chairman and CEO, Paul Mann.

Key Points: 
  • WASHINGTON, April 11, 2024 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. NASDAQ: ASPI ("ASPI,” or the “Company”), an advanced materials company dedicated to the development of technology and processes designed to produce isotopes used in multiple industries, today released the following letter to stockholders from its Chairman and CEO, Paul Mann.
  • The contract required RC14 to provide an irrevocable standby letter of credit in lieu of a deposit, which was received.
  • Our proprietary technology has proven capabilities to enrich a wide range of isotopes, including light isotopes and lighter molecules, such as silane (SiH4).
  • ASP Isotopes’ goal is to become the lowest cost and most reliable supplier of stable isotopes globally.

Pioneering Nuclear Technology Firm, Curio, Closes $14 Million Seed Round to Drive Clean Energy Innovation

Retrieved on: 
金曜日, 4月 19, 2024
Public sector, DOE, GAIN, Converters (industry), PNNL, Partnership, PIA, Cooperative, CURIE, Primary energy, Radionuclide, ARPA, Oak Ridge National Laboratory, INL, Moskowitz, Renewable energy

WASHINGTON, April 18, 2024 /PRNewswire/ -- Curio Legacy Ventures, Inc., a Washington DC-based company dedicated to advancing a closed fuel cycle through innovative technologies like NuCycle®, a revolutionary nuclear waste recycling technology, proudly announces the successful closure of its seed round with a total haul of $14 million. This achievement signifies a significant step forward in the company's mission to establish clean nuclear power as a catalyst for global prosperity and sustainability.

Key Points: 
  • This achievement signifies a significant step forward in the company's mission to establish clean nuclear power as a catalyst for global prosperity and sustainability.
  • Our commitment to developing pivotal and transformational nuclear technologies for a closed and sustainable nuclear cycle underscores our belief in seizing the future of energy.
  • Clean nuclear power serves as the cornerstone of our mission, envisioning a world where the United States leads as the leading nuclear energy exporter and supplier of nuclear fuel, energy, and next-generation radioisotopes and nuclides."
  • Looking ahead, Curio plans to leverage the success of its seed round to bridge towards further development, expanding its portfolio of technology advancements.

Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Developments

Retrieved on: 
木曜日, 3月 28, 2024
Cancer, Receptor (biochemistry), Radionuclide, Patient, Neoplasm, PET, G&A, Worldwide Angel, Actinium-225, MTIC, Pancreatic cancer, Investment, Fifth, Therapy, Clinical trial, Safety

WILMETTE, Ill., March 28, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced fourth quarter and full-year 2023 financial results and summarized recent developments.

Key Points: 
  • WILMETTE, Ill., March 28, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced fourth quarter and full-year 2023 financial results and summarized recent developments.
  • Results for the Fourth Quarter and Year Ended December 31, 2023, Compared to the Fourth Quarter and Year Ended December 31, 2022
    Cash, cash equivalents and short-term investments as of December 31, 2023, were $7.3 million.
  • R&D expenses for the fourth quarter of 2023 were $1.0 million compared to $2.1 million for the fourth quarter of 2022.
  • G&A expenses for the fourth quarter of 2023 were $0.9 million, compared to $0.8 million for the fourth quarter of 2022.

Molecular Partners Reports Corporate Highlights From Q4 2023 and Key Financials for Full Year 2023

Retrieved on: 
木曜日, 3月 14, 2024
CD33, GSK, Patient, Macrophage, Society, CD3, CD47, DLL3, Therapy, Molecular Partners, TME, Partner, DRS, ASH, AML, SNMMI, Partnership, RDT, Radionuclide, Tetra, Novartis, HSCT, MHS, FTE, Exposition, Delta, Safety, SITC, Amgen, Hematopoietic stem cell transplantation, FAP, Disease, Nuclear medicine, Immunotherapy, District court, Neoplasm, EANM, Alpha particle, JNJ, Tumor microenvironment, Gene family, CD70, AACR, CD40, CHF, CD123, NK, Engineering, Antigen, Molecule, Annual general meeting, Toxicity, CD16, B cell, Conference, MBA, DARPin, Data, Molecular imaging, Pharmaceutical industry

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 14, 2024 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced its corporate highlights and audited financial results for the full year 2023.

Key Points: 
  • 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced its corporate highlights and audited financial results for the full year 2023.
  • “2023 was a year of successful innovation and execution on our strategy, focusing on novel mechanisms that we believe only DARPin therapies can deliver.
  • In addition to the above updates, Molecular Partners continued to progress its RDT portfolio of projects in partnership with Novartis.
  • In the financial year 2023, Molecular Partners recognized total revenues and other income of CHF 7.0 million (2022: CHF 189.6 million) and incurred total expenses of CHF 68.1 million (2022: CHF 73.0 million).